Cognosci Inc, based in Durham, NC, is a pioneering biotech company focused on discovering and developing therapeutic compounds for the treatment of various neurological and inflammatory diseases. Their small patented synthetic peptides, based on the multifunctional apoE protein, exhibit potent anti-inflammatory activity and provide direct neuroprotection by blocking neurotoxins released by injured brain cells.
With a deep pipeline of programs in different stages of development, Cognosci aims to identify efficacious compounds through predictive animal models and advance them to Phase II human clinical trials. Their groundbreaking approach, combining immune suppression and direct neuroprotection, is revolutionizing the treatment paradigms for conditions such as Multiple Sclerosis, Traumatic Brain Injury, Stroke, Subarachnoid Hemorrhage, Spinal Cord Injury, and Rheumatoid Arthritis.
Generated from the website